Cargando…

Exacerbation of chronic renal failure because of inhaled tobramycin in a lung transplant patient

61-year-old man, with a history of years of unknown etiology bronchiectasis, with chronic bronchial infection by Burkholderia multivorans, who received treatment with a double lung transplant on 08/20/2020. Persistent positive cultures of Burkholderia multivorans after transplant in respiratory samp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mora Cuesta, Víctor M., Borja Vargas, Noelia, Iturbe Fernández, David, Tello Mena, Sandra, Cifrián Martínez, José M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803646/ https://www.ncbi.nlm.nih.gov/pubmed/35127435 http://dx.doi.org/10.1016/j.rmcr.2022.101584

Ejemplares similares

Cost Reduction of Inhaled Tobramycin by Use of Preservative-Free Intravenous Tobramycin Given via Inhalation
por: Gauthier, Timothy P., et al.
Publicado: (2015)

DQA1 Eplet Mismatch Load As an Independent Risk Factor of CLAD After Lung Transplantation
por: González-López, Elena, et al.
Publicado: (2023)

Efficacy of inhaled tobramycin in severe nosocomial pneumonia
por: Kuzovlev, A, et al.
Publicado: (2012)

Inhaled tobramycin for the treatment of nosocomial pneumonia in sepsis
por: Kuzovlev, A, et al.
Publicado: (2014)

Adherence with tobramycin inhaled solution and health care utilization
por: Briesacher, Becky A, et al.
Publicado: (2011)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Early preventive administration of inhaled tobramycin in severe polytrauma
por: Kuzovlev, A, et al.
Publicado: (2015)

Double-Lung Transplantation in a Patient with Pulmonary Type B Niemann-Pick Disease: A Valid Treatment Option
por: Mora, Víctor Manuel, et al.
Publicado: (2022)

Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis
por: Terpstra, Lotte C., et al.
Publicado: (2022)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Lack of concordance between the different exercise test measures used in the risk stratification of patients with pulmonary arterial hypertension
por: Mora Cuesta, Víctor M., et al.
Publicado: (2022)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
por: Thornton, Christina, et al.
Publicado: (2021)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis
por: MacLeod, David L., et al.
Publicado: (2009)

Myeloid-Derived Suppressor Cells Are Increased in Lung Transplant Recipients and Regulated by Immunosuppressive Therapy
por: Iglesias-Escudero, María, et al.
Publicado: (2022)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
por: Greenwood, James, et al.
Publicado: (2017)

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
por: Hamed, Kamal, et al.
Publicado: (2017)

Comparing inhaled colistin with inhaled fosfomycin/tobramycin as an adjunctive treatment for ventilator‐associated pneumonia: An open‐label randomized controlled trial
por: Hakamifard, Atousa, et al.
Publicado: (2023)

Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?
por: Karki, Kumar, et al.
Publicado: (2021)

Calcineurin inhibitors’ impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain
por: Nogueiras-Álvarez, Rita, et al.
Publicado: (2022)

Acute renal failure due to tobramycin intoxication during selective digestive tract decontamination
por: Ramnarain, D., et al.
Publicado: (2011)

Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2023)

Unknown Renal Impairment: A Rare Case of Inhaled Tobramycin Induced Acute Kidney Injury in a Cystic Fibrosis Patient
por: Miller, Tyler, et al.
Publicado: (2021)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients
por: Hoppentocht, Marcel, et al.
Publicado: (2016)

Evaluation of Two Different CMV-Immunoglobulin Regimens for Combined CMV Prophylaxis in High-Risk Patients following Lung Transplant
por: Mora, Víctor M., et al.
Publicado: (2022)

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
por: Lam, John, et al.
Publicado: (2013)

Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
por: Panguluri, Srilekha, et al.
Publicado: (2017)

Acute Renal Failure due to a Tobramycin and Vancomycin Spacer in Revision Two-Staged Knee Arthroplasty
por: Patel, Ronak A., et al.
Publicado: (2018)

COVID-19 pneumonia affecting only native lung in one-lung transplantation()
por: Mora Cuesta, Víctor Manuel, et al.
Publicado: (2021)

Assessing tobramycin levels and renal function following the implantation of CaSO(4) beads impregnated with tobramycin: A prospective cohort study
por: Alowais, Shuroug A., et al.
Publicado: (2022)

The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison
por: Prayle, A.P., et al.
Publicado: (2016)

Tobramycin and vestibulotoxicity: retrospective analysis of four cases
por: Vonk, S E M, et al.
Publicado: (2022)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

In Vitro Synergy of Cefamandole-Tobramycin Combinations
por: Valenti, August J., et al.
Publicado: (1977)

Tobramycin Nanoantibiotics and Their Advantages: A Minireview
por: Rosalia, Mariella, et al.
Publicado: (2022)

Collateral Sensitivity to Fosfomycin of Tobramycin-Resistant Mutants of Pseudomonas aeruginosa Is Contingent on Bacterial Genomic Background
por: Genova, Roberta, et al.
Publicado: (2023)

Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report
por: Santos, Roberto P, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_hd8vu8g2m9o8del4cvna0chct3